The Claim
In obese males, a 72-hour fasting period increases endogenous growth hormone levels and reduces insulin-like growth factor I (IGF-I), and pharmacological blockade of growth hormone with pegvisomant further suppresses IGF-I, demonstrating that pegvisomant inhibits growth hormone signaling in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese men, not eating for 72 hours raises growth hormone levels and lowers IGF-I levels; when growth hormone signaling is blocked with pegvisomant, IGF-I levels drop further, confirming that pegvisomant blocks growth hormone activity in this group.
See the scientific wording
In obese males, 72-hour fasting increases endogenous growth hormone levels and reduces insulin-like growth factor I (IGF-I), and pharmacological GH blockade further suppresses IGF-I, confirming that pegvisomant effectively inhibits GH signaling in this population.
When a person fasts for three days, the body releases more growth hormone, which normally tells the liver to make IGF-I. But when a drug blocks growth hormone from acting on the liver, the liver stops making IGF-I even more. This happens because the growth hormone signal is cut off, so the liver cannot produce IGF-I, and the body's natural rise in growth hormone during fasting is not enough to overcome this block.
What the research says
1 studyWhen obese men fast for three days, their bodies naturally make more growth hormone and less IGF-I. When they also take a drug that blocks growth hormone, IGF-I drops even more — proving the drug works as intended.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.